InvestorsHub Logo

RedShoulder

10/29/20 7:23 PM

#279388 RE: Doc328 #279381

Doc, thanks for your well thought out and detailed response.

Good luck with treating all your patients.

What do you think of A2-73 possibility getting early FDA approval during their upcoming Phase-3 Alzheimer trail while in late progress; considering first of all the safety indications of the drug, but most of all the dire need of suffers 'if' it shows excellent efficacy, and notable improvement or stabilization among a significant percentage of the trial patients?

frrol

10/29/20 7:39 PM

#279389 RE: Doc328 #279381

It's a tough call for the FDA. And there are enormous Medicare implications.